Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) Director Equity Cof Lp Bios purchased 71,428 shares of the stock in a transaction on Friday, June 27th. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the acquisition, the director directly owned 196,428 shares in the company, valued at approximately $1,374,996. This trade represents a 57.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Actuate Therapeutics Stock Down 3.2%
Shares of NASDAQ ACTU traded down $0.22 during midday trading on Thursday, reaching $6.53. 53,986 shares of the company traded hands, compared to its average volume of 58,310. Actuate Therapeutics, Inc. has a 12 month low of $5.50 and a 12 month high of $11.99. The stock's 50-day simple moving average is $8.95 and its 200-day simple moving average is $8.27.
Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06).
Institutional Trading of Actuate Therapeutics
Large investors have recently made changes to their positions in the business. BIOS Capital Management LP bought a new position in shares of Actuate Therapeutics in the fourth quarter valued at about $78,753,000. Envestnet Asset Management Inc. acquired a new stake in Actuate Therapeutics in the 4th quarter valued at about $83,000. Mercer Global Advisors Inc. ADV acquired a new stake in Actuate Therapeutics in the 4th quarter valued at about $130,000. Voss Capital LP bought a new position in shares of Actuate Therapeutics in the fourth quarter worth about $440,000. Finally, Sigma Planning Corp acquired a new position in shares of Actuate Therapeutics during the fourth quarter worth approximately $128,000.
Analyst Upgrades and Downgrades
A number of brokerages have commented on ACTU. Craig Hallum initiated coverage on shares of Actuate Therapeutics in a research note on Tuesday, April 22nd. They set a "buy" rating and a $21.00 price target for the company. HC Wainwright increased their target price on Actuate Therapeutics to $20.00 and gave the stock a "buy" rating in a report on Tuesday, June 3rd.
Get Our Latest Research Report on ACTU
Actuate Therapeutics Company Profile
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Featured Articles
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
